MP2021 : Competitive Inhibitor for TM4SF19
- MP2021 targets TM4SF19, a novel protein involved in osteoclast formation
- MP2021 is a Fc-fusion protein that competitively inhibits TM4SF19.
- Osteoclast differentiation is inhibited in both KO and LELΔ osteoclasts, resulting in increased bone mass, and that the LEL region of TM4SF19 is required for its function.
- Efficacy
Significantly inhibits bone-loss and restores bone balance (Rheumatoid Arthritis, Osteoporosis)
Inhibition of bone metastasis (anticancer)
Inhibition of muscle loss
Reduction of visceral white fat (fatty liver prevention)
- Potential to expand to broader bone diseases and healthy aging
Efficacy study for IND completed
Significantly inhibits bone-loss and restores bone balance in osteoporotic model.
Confirmed improvement in BMD, BV/TV, Tb.N, and Tb.Sp.
Suppresses adipocyte differentiation and inflammation, prevent obesity and bone loss, and promote browning of white adipose tissue to enhance thermogenesis.
TOX study for IND completed
Highest dose selected as the NOAEL
Safe due to distinctive MoA of TM4SF19.